Browse EX-10 agreements

EXHIBIT 10.3

February 26, 2025

Jonathan Volkmann

[ ]

[ ]

Re: Promotion to SVP, Global Operations

Dear Jon,

I am very pleased to congratulate you on your promotion to the position of SVP, Global Operations of WW International, Inc. (“WW” or the “Company”), reporting to Tara Comonte, Interim President and Chief Executive Officer. This promotion recognizes both the significant contributions you have made, and the expanded impact we anticipate you will have on the business in the future. The details associated with your new role are outlined below.

Effective Date: January 20, 2025

Base Salary: Your new salary will be $385,000.00 per year, less applicable deductions and withholdings. You will be classified as an exempt employee and will therefore not be eligible for overtime.

…

CONFIDENTIAL SETTLEMENT AGREEMENT
AND GENERAL RELEASE AND WAIVER OF CLAIMS

This Confidential Settlement Agreement and General Release (the “Agreement”) is entered into by and between, on the one hand, Tara Comonte (“Comonte”), and on the other hand, WW International, Inc. (“WW”). The aforementioned are each referred to herein as a “Party,” and, collectively, as the “Parties.”

WHEREAS, Comonte was employed by WW in the role of President and Chief Executive Officer;

WHEREAS, on March 30, 2026, Comonte notified the board of directors (the “Board”) of WW of her resignation as President and Chief Executive Officer, effective March 31, 2026, and the Board accepted Comonte’s resignation;

…

LIVERAMP HOLDINGS, INC.

AMENDED AND RESTATED 2005 EQUITY COMPENSATION PLAN

NOTICE OF PERFORMANCE UNIT AWARD AND PERFORMANCE UNIT AGREEMENT (CALIFORNIA EMPLOYEES)

%%FIRST_NAME_MIDDLE_NAME_LAST_NAME%-%
%%ADDRESS_LINE_1%-%
%%ADDRESS_LINE_2%-%
%%CITY_STATE_ZIPCODE%-%
%%COUNTRY%-%

…

LIVERAMP HOLDINGS, INC.

AMENDED AND RESTATED 2005 EQUITY COMPENSATION PLAN

NOTICE OF PERFORMANCE UNIT AWARD AND PERFORMANCE UNIT AGREEMENT

%%FIRST_NAME_MIDDLE_NAME_LAST_NAME%-%
%%ADDRESS_LINE_1%-%
%%ADDRESS_LINE_2%-%
%%CITY_STATE_ZIPCODE%-%
%%COUNTRY%-%

…

Symbotic LLC 200 Research Drive | Wilmington, MA 01887 Phone 978-284-2800 | www.symbotic.com May 6, 2026 James Kuffner c/o Symbotic Inc. 200 Research Drive Wilmington, MA 01887 Re: Corporate Apartment Dear James: On June 6, 2025, you signed a letter agreement with Symbotic LLC (the “Company”) regarding temporary accommodations near the headquarters of the Company in Wilmington, Massachusetts (“Letter Agreement”). The Letter Agreement terminated on April 30, 2026. This letter amends and restates the terms of your temporary accommodations subject to your continued employment with the Company or any of its subsidiaries. If you understand and agree to these terms, please sign at the end of this letter. 1. Beginning on June 6, 2025, the Company will provide you access to a furnished corporate apartment with two bedrooms and two bathrooms at the Life Time Living Burlington apartment complex. 2. You may use the apartment on a temporary basis as the Company’s guest and at its sole and absolute discretion. Whom you allow into the apartment as your guest (including family, colleagues, friends

…

CERTAIN INFORMATION IN THIS DOCUMENT, MARKED BY [**], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(b)(10)(iv). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL.

SEVENTH AMENDMENT TO

SERVICE AGREEMENT

THIS SEVENTH AMENDMENT TO SERVICE AGREEMENT (“Amendment”) is entered into as of April 29, 2026 (“Amendment Effective Date”), by and betweenDave Operating LLC f.k.a. Dave, Inc., a Delaware limited liability company (“Customer”), and Galileo Financial Technologies, LLC, a Delaware limited liability company (“Galileo”).

A. Customer and Galileo are parties to that certain Service Agreement dated March 18, 2020, as amended (“Agreement”) and supplemented including by addenda from time to time. Capitalized terms used herein but not defined have the meanings given to them in the Agreement.

B. Pursuant to Section 12.9 of the Agreement, the Agreement may be amended upon the written approval of Customer and Galileo. Customer and Galileo desire to amend the Agreement as set forth herein.

…

July 13, 2026

Aziz Mottiwala

[***]

Re: Employment Letter

Dear Aziz,

This letter agreement (the “Agreement”) is entered into between Aziz Mottiwala (“you”) and RxSight, Inc. (the “Company” or “we”). This Agreement is effective upon execution and your employment with the Company will commence on July 20, 2026 (the “Start Date”). The purpose of this Agreement is to confirm the terms and conditions of your employment.

1.

Position. Your position will be President andChief Executive Officer, and you will report to the Company’s Board of Directors (the “Board”). This is a full-time position. You will perform the duties and have the responsibilities and authority customarily performed and held by an employee in your position or as otherwise may be assigned or delegated to you by the Board. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full-time or part-time) that would create a conflict of interest with the Company. By signing this Agreement, you reconfirm to the Company that you have no contr

…

July 13, 2026

Ron Kurtz

c/o RxSight, Inc.

100 Columbia,

Aliso Viejo, CA 92656

Re: Transition Employment Letter

Dear Ron:

This letter agreement (the “Agreement”) is entered into between Ron Kurtz (“you”) and RxSight, Inc. (the “Company” or “we”). This Agreement will be effective as of July 20, 2026 (the“Effective Date”). The purpose of this Agreement is to confirm the terms and conditions of your employment.

1.

Position. Commencing on the Effective Date, your position with the Company will be Chief Medical Officer, and you will report to the Company’s Chief Executive Officer or to such other person as the Company subsequently may determine. This is a full-time position. You will perform the duties and have the responsibilities and authority customarily performed and held by an employee in your position or as otherwise may be assigned or delegated to you by the Company. While you render services to the Company, you will not engage in any other employment, consulting or other business activity (whether full‑time or part-time) that would create a conflict of interest with the C

…

Rxsight, INC.

AMENDED AND RESTATED CHANGE IN CONTROL SEVERANCE AGREEMENT

This Amended and Restated Change in Control Severance Agreement (the “Agreement”) is made between RxSight, Inc. (the “Company”) and Ron Kurtz (the “Executive”), effective as of July 20, 2026 (the “Effective Date”).

This Agreement provides certain protections to the Executive in connection with a change in control of the Company or in connection with the involuntary termination of the Executive’s employment under the circumstances described in this Agreement. Certain capitalized terms are defined in Section 8 to the extent not otherwise defined in other Sections of the Agreement.

The Company and the Executive agree as follows:

1.

Term of Agreement. This Agreement will terminate upon the date that all of the obligations of the parties hereto with respect to this Agreement have been satisfied.

2.

At-Will Employment. The Company and the Executive acknowledge that the Executive’s employment is and will continue to be at-will, as defined under applicable law.

3.

Severance Benefits.

(a)

…

RXSIGHT, INC.

CHANGE IN CONTROL SEVERANCE AGREEMENT

This Change in Control Severance Agreement (the “Agreement”) is made between RxSight, Inc. (the “Company”) and Aziz Mottiwala (the “Executive”), effective as of July 20, 2026 (the “Effective Date”).

This Agreement provides certain protections to the Executive in connection with a change in control of the Company or in connection with the involuntary termination of the Executive’s employment under the circumstances described in this Agreement. Certain capitalized terms are defined in Section 8to the extent not otherwise defined in other Sections of the Agreement.

The Company and the Executive agree as follows:

1.

Term of Agreement. This Agreement is effective as of the Effective Date and will terminate upon the date that all of the obligations of the parties hereto with respect to this Agreement have been satisfied.

2.

At-Will Employment. The Company and the Executive acknowledge that the Executive’s employment is and will continue to be at-will, as defined under applicable law.

3.

Severance Benefits.

(a)

…

Rxsight, INC.

AMENDMENT TO CHANGE IN CONTROL AND SEVERANCE AGREEMENT

This Amendment to Change in Control and Severance Agreement (the “Amendment”) is made by and between RxSight, Inc. (the “Company”) and Ron Kurtz (the “Executive”), effective as of April 17, 2026 (the “Effective Date”).

WHEREAS, the Company and Executive previously entered into a Change in Control and Severance Agreement effective as of July 16, 2021 (the “Agreement”);

WHEREAS, the Company and Executive have agreed to amend the Agreement to increase certain severance benefits provided for under the Agreement in the event of the Executive’s Qualifying CIC Termination (as defined in the Agreement); and

WHEREAS, unless defined otherwise, the defined terms in this Amendment shall have the same meanings in the Agreement.

NOW, THEREFORE, in consideration of the foregoing, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and Executive, intending legally to be bound, hereby agree as follows:

I.

…

Certain identified information has been excluded from the exhibit because it is both (i) not material and (ii) is the type that the company treats as private or confidential.

LICENSE, COLLABORATION AND DEVELOPMENT AGREEMENT

by and between

ALCON PHARMACEUTICALS,LTD

and

RXSIGHT,INC.

June 30, 2026

i

---

TABLE OF CONTENTS

Article 1. DEFINITIONS 1

Article 2. LICENSES 21

Article 3. DEVELOPMENT 25

Article 4. GOVERNANCE 35

Article 5. TECHNOLOGY DISCLOSURE 37

Article 6. COMMERCIALIZATION, REGULATORY AND MANUFACTURING 38

Article 7. FINANCIAL PROVISIONS 44

Article 8. REPORTS AND PAYMENT TERMS 51

Article 9. INTELLECTUAL PROPERTY RIGHTS 54

Article 10. CONFIDENTIALITY 63

Article 11. TERM AND TERMINATION 67

Article 12. EFFECTS OF EXPIRATION OR TERMINATION 70

Article 13. REPRESENTATIONS AND WARRANTIES; COVENANTS 76

Article 14. INDEMNIFICATION AND LIABILITY 86

Article 15. COMPLIANCE 90

Article 16. GENERAL PROVISIONS 93

Exhibits

Exhibit A Baseball Arbitration

Exhibit B Demand Generation Activities

Exhibit C Industry Participants

Exhibit D Development Plan

…